Oral Vitamin D Supplementation Prevent Peritoneal Dialysis-related Peritonitis
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age19+
SponsorPeking University First Hospital
About this trial
This is a multicenter randomized, placebo-controlled trial of Vitamin D supplementation in patients on peritoneal dialysis to determine whether oral administration of vitamin D3 after curing an episode of peritonitis could reduce the risk of subsequent peritoneal dialysis-related peritonitis.
Eligibility criteria
Qualifiers
Medically stable and receiving peritoneal dialysis for > 1 month
Older than 18 years old
Serum 25(OH)D < 30ng/ml
Adequate dialysis on evaluation with weekly Kt/V ≥ 1.5, or (revised time: 2023-7-11) without clinical uremic symptoms
Disqualifiers
Receive Vitamin D2/D3 during the previous 1 month (revised time: 2023-7-11) ;
History of allergic reaction to Cholecalciferol;
Current or past malignant disease, active hepatitis or hepatic failure, active autoimmune disease, severe digestive malabsorption or an eating disorder, HIV/AIDS;
Acute systemic infection, cardiovascular disease, surgery, or trauma in the last month;
Trial design
Treatments tested in this trial
- Cholecalciferol
- Placebo
Treatment groups
176 Participants
are divided into 2 treatment groupsSponsors and collaborators
Peking University First Hospital
Lead sponsor
Peking University Third Hospital
Collaborator
Peking University People's Hospital
Collaborator
Beijing Haidian Hospital
Collaborator
Peking University Shenzhen Hospital
Collaborator
Beijing Fangshan District Hospital of Traditional Chinese Medicine
Collaborator
Peking University International Hospital
Collaborator
Beijing Tsinghua Changgeng Hospital
Collaborator
Beijing Anzhen Hospital
Collaborator
Capital Medical University
Collaborator
Source ClinicalTrials.gov